Effect of Feitai Capsule (肺泰胶囊) on quality of life and progression-free survival of patients with unresectable non-small cell lung cancer

Zong-yang Yu; Zhi-zhen Liu; Xue-nong Ouyang; Jian Du; Xi-hu Dai; Xi Chen; Zhong-quan Zhao; Wen-wu Wang; Jie Li

doi:10.1007/s11655-012-0994-1

Your Location：

Home >

Browse articles >

Effect of Feitai Capsule (肺泰胶囊) on quality of life and progression-free survival of patients with unresectable non-small cell lung cancer

Updated：2021-08-27

- Effect of Feitai Capsule (肺泰胶囊) on quality of life and progression-free survival of patients with unresectable non-small cell lung cancer
- Chinese Journal of Integrative Medicine Vol. 18, Issue 2, Pages: 106-111(2012)
- Affiliations：
  
  1. Department of Oncology, Fuzhou General Hospital, Nanjing Military Command,Fuzhou,China
  2. Fujian Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine,Fuzhou,China
- Author bio：
- Funds：
  
  Supported by the Key Subject of People’s Liberation Army Eleventh-Five-Year Traditional Chinese Medicine Clinical Research Program (No. 2006051002)
- DOI：10.1007/s11655-012-0994-1
  CLC：
- Published：2012，
  
  Published Online：5 February 2012，
Scan for full text
Yu, Zy., Liu, Zz., Ouyang, Xn. et al. Effect of Feitai Capsule (肺泰胶囊) on quality of life and progression-free survival of patients with unresectable non-small cell lung cancer., Chin. J. Integr. Med. 18, 106–111 (2012). https://doi.org/10.1007/s11655-012-0994-1

Zong-yang Yu, Zhi-zhen Liu, Xue-nong Ouyang, et al. Effect of Feitai Capsule (肺泰胶囊) on quality of life and progression-free survival of patients with unresectable non-small cell lung cancer. [J]. Chinese Journal of Integrative Medicine 18(2):106-111(2012)
Yu, Zy., Liu, Zz., Ouyang, Xn. et al. Effect of Feitai Capsule (肺泰胶囊) on quality of life and progression-free survival of patients with unresectable non-small cell lung cancer., Chin. J. Integr. Med. 18, 106–111 (2012). https://doi.org/10.1007/s11655-012-0994-1 DOI：

Zong-yang Yu, Zhi-zhen Liu, Xue-nong Ouyang, et al. Effect of Feitai Capsule (肺泰胶囊) on quality of life and progression-free survival of patients with unresectable non-small cell lung cancer. [J]. Chinese Journal of Integrative Medicine 18(2):106-111(2012) DOI： 10.1007/s11655-012-0994-1.

摘要

To examine the effect of a Chinese medicinal herbal formula (Feitai Capsule

肺泰胶囊) on the quality of life (QOL) and progression-free survival (PFS) of patients with unresectable non-small cell lung cancer (NSCLC). Sixty-two patients were randomly divided into the treatment group (31 cases) and the control group (31 cases). For the treatment group

4 capsules (1.2 g/capsule) of Feitai Capsule were administered 3 times a day after meals for 3 weeks; then no drug was administered for 1 week. This schedule was continued for at least 3 more cycles (12 weeks totally). If there were no obvious toxic reactions

the treatment was extended. The patients were evaluated at least once every 8 weeks until progressive disease (PD). For the control group

the regular follow-up and evaluation were performed at least once every 8 weeks until PD. Clinical symptoms

objective response

physical constitution and energy

QOL

and PFS were evaluated regularly. Analysis of variance (ANOVA)

a non-parametric test

and analysis of covariance were used to compare clinical features

amelioration of clinical symptoms

physical constitution and energy

and QOL. Kaplan-Meier analysis was used to compare the two-group PFS. Sixty patients finished the final evaluation

with 30 patients in each group. Baseline characters between groups were not significantly different (P>0.05). The control group had a 36.7% improvement in clinical symptoms

while the treatment group had a 73.3% improvement. This difference was statistically significant (Z= −2.632

P=0.008). The control group had a 26.7% improvement in the Karnofsky performance status (KPS)

while the treatment group had a 53.4% improvement. This was also significantly different (Z=−2.182

P=0.029). A comparative analysis indicated a positive correlation (r=0.917

P<0.001). Compared with the control group

QOL in the treatment group was significantly improved

except in the social/family condition and doctor-patient relationship indicators. The PFS of the treatment group and control group were 6.23 months and 4.67 months

respectively (P=0.048). Feitai Capsule

a Chinese medicinal herbal treatment could improve the QOL and extend the PFS of the unresectable NSCLC patients.

Abstract

To examine the effect of a Chinese medicinal herbal formula (Feitai Capsule

the treatment was extended. The patients were evaluated at least once every 8 weeks until progressive disease (PD). For the control group

the regular follow-up and evaluation were performed at least once every 8 weeks until PD. Clinical symptoms

objective response

physical constitution and energy

QOL

and PFS were evaluated regularly. Analysis of variance (ANOVA)

a non-parametric test

and analysis of covariance were used to compare clinical features

amelioration of clinical symptoms

physical constitution and energy

and QOL. Kaplan-Meier analysis was used to compare the two-group PFS. Sixty patients finished the final evaluation

with 30 patients in each group. Baseline characters between groups were not significantly different (P>0.05). The control group had a 36.7% improvement in clinical symptoms

while the treatment group had a 73.3% improvement. This difference was statistically significant (Z= −2.632

P=0.008). The control group had a 26.7% improvement in the Karnofsky performance status (KPS)

while the treatment group had a 53.4% improvement. This was also significantly different (Z=−2.182

P=0.029). A comparative analysis indicated a positive correlation (r=0.917

P<0.001). Compared with the control group

QOL in the treatment group was significantly improved

except in the social/family condition and doctor-patient relationship indicators. The PFS of the treatment group and control group were 6.23 months and 4.67 months

respectively (P=0.048). Feitai Capsule

a Chinese medicinal herbal treatment could improve the QOL and extend the PFS of the unresectable NSCLC patients.

关键词

non-small cell lung cancerChinese MedicineFeitai Capsulemaintenance treatmentquality of lifeprogression-free survival

Keywords

non-small cell lung cancerChinese MedicineFeitai Capsulemaintenance treatmentquality of lifeprogression-free survival

references

NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008;26:4617–4625.

Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tunlors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727–1733.

Lin LZ, Zhou DH, Zheng XT. Effect of traditional Chinese medicine in improving quality of life of patients with nonsmall cell Lung cancer in late stage. Chin J Integr Tradit West Med (Chin) 2006;26:389–393.

Sun HX, Qin J, Zhou YQ. Influence of Xiaoliu Baofei Pill combined with chemotherapy on quality of life of patients with advanced non-small cell lung cancer. Chin J Integr Tradit West Med (Chin) 2009;29:23–25.

Wu J, Xu ZY, Wang ZQ, Zhou WD, Deng HB, Zhao XZ, et al. Clinical study on treatment of advanced non-small cell lung cancer with Kangliu Zengxiao Decoction. Chin J Integr Tradit West Med (Chin) 2010;30:137–140.

Zheng XY. The Clinical Research Instructive Principle on TCM New Medication. 12th ed. Beijing: China Medical Science Press; 2002:216–219.

Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 1995;12:199–220.

Therasse P, Arbuck SG. New guidelines to evaluate the response to treatment in solid tumors. Nat Cancer Inst 2000;92:205–216.

Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543–3551.

Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, et al. SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol 2009;27:8001.

Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, et al. America Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330–353.

Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramlau R, Ghilezan N. Central European Cooperative Oncology Group (CECOG). Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006;52:155–163.

Barata FJ, Parente BT, Encarnacao N, Fernando F, Ana C, Joao A, et al. Optimal duration of chemotherapy in non-small-cel lung cancer: multicenter, randomized, prospective clinical trial comparing 4 vs. 6 cycles of carboplatin and gemcitabine. J Thorac Oncol 2007;2(8 Suppl 4):S666.

Westeel V, Quoix E, Moro-Sibilot D, Mercier M, Breton JL, Debieuvre D, et al. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst 2005;97:499–506.

FULL TEXT LINK

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Standardized treatment of chinese medicine decoction for cancer pain patients with opioid-induced constipation: A multi-center prospective randomized controlled study

Clinical study on long-term overall survival of advanced non-small-cell lung cancer patients treated with Chinese medicine and western medicine

Effectiveness of Bufei Yishen Granule (补肺益肾颗粒) combined with acupoint sticking therapy on quality of life in patients with stable chronic obstructive pulmonary disease

Chinese medicine improves postoperative quality of life in endometriosis patients: A randomized controlled trial

Clinical benefits as endpoints in advanced non-small cell lung cancer treated with integrative medicine

Related Author

No data

Related Institution

Department of Oncology, First Affiliated Hospital of Guangzhou University of Chinese Medicine

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Integrated Traditional Chinese and Western Medicine, Peking University Cancer Hospital & Institute

Dongzhimen Hospital, Beijing University of Chinese Medicine

The Geriatric Department, Henan University of Traditional Chinese Medicine

Department of Respiratory, the First Affiliated Hospital of Henan University of Traditional Chinese Medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰